Opus Genetics (IRD) Cash & Equivalents Growth (3y) (2013 - 2026)
Powered by 
Analysis
Opus Genetics (IRD) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -23.18% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 14.34% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 37.45% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -27.97% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.85% |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | 30.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.46% |
| Mar 31, 2026 | 15.44% |
| Dec 31, 2025 | 1.89% |
| Sep 30, 2025 | 30.53% |
| Jun 30, 2025 | 23.96% |
| Mar 31, 2025 | 29.50% |
| Dec 31, 2024 | 7.31% |
| Sep 30, 2024 | 18.08% |
| Jun 30, 2024 | 19.55% |
| Mar 31, 2024 | 64.53% |
| Dec 31, 2023 | 45.49% |
| Sep 30, 2023 | 73.78% |
| Jun 30, 2023 | 63.16% |
| Mar 31, 2023 | 52.49% |
| Dec 31, 2022 | 202.71% |
| Sep 30, 2022 | 20.43% |
| Jun 30, 2022 | 32.55% |
| Mar 31, 2022 | 46.49% |
| Dec 31, 2021 | 41.04% |
| Sep 30, 2021 | 69.22% |